Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eribulin

- PMLiVE

NHS to move ahead with Pfizer/BioNTech bivalent COVID-19 vaccine roll-out

The autumn booster programme launches today

- PMLiVE

Bristol Myers Squibb’s acute myeloid leukaemia oral maintenance therapy recommended by NICE

Phase 3 trial results show Onureg offers significantly longer overall and relapse-free survival

- PMLiVE

ALL CHANGE FOR SPECIALISED COMMISSIONING: FOUR THINGS INDUSTRY NEEDS TO KNOW ABOUT THE LATEST REFORMS

With a recent NHSEI policy document confirming that a major shake-up of arrangements for Specialised Commissioning is imminent, Oli Hudson, Content Director at Wilmington Healthcare (wilmingtonhealthcare.com), describes the key changes...

Wilmington Healthcare

- PMLiVE

NHS leaders urge government to take action on energy costs or risk ‘public health emergency’

There are concerns that widespread fuel poverty will increase the already high number of annual deaths associated with cold homes – estimated at around 10,000 a year

- PMLiVE

Gilead Sciences announce positive results for Trodelvy in breast cancer patients

HR+/HER2- breast cancer accounts for around 70% of all new cases, or nearly 400,000 diagnoses worldwide each year

- PMLiVE

AstraZeneca and Daiichi Sankyo get FDA approval for breast cancer drug

Results from a phase 3 trial showed Enhertu reduced the risk of disease progression or death by 50%

- PMLiVE

NHS England launches hepatitis C screening scheme to reach 2030 elimination goal

The new scheme could help diagnose up to 80,000 people who do not know they have hepatitis C

- PMLiVE

NHS England to roll out continuous glucose monitors to all those with type 1 diabetes

The wearable monitor sends information to a mobile app, allowing those with diabetes to easily keep track of their glucose levels at all times

- PMLiVE

Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer’s disease

Eisai presented the data at the Alzheimer’s Association International Conference (AAIC)

- PMLiVE

NICE recommends Rhythm Pharmaceuticals’ Imcivree for severe obesity and hyperphagia

The treatment will be funded and available for use within 90 days in the NHS

- PMLiVE

Bristol Myers Squibb announces NICE recommendation for Opdivo plus Yervoy to treat unresectable malignant pleural mesothelioma

The treatment combination is the first immunotherapy of its kind in over ten years to be made available via the NHS

- PMLiVE

NICE recommends Novartis’ Piqray in combination with Faslodex for advanced breast cancer patients

Around 2,800 breast cancer patients in England and Wales could benefit from the treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links